TiumBio Co., Ltd. Logo

TiumBio Co., Ltd.

Clinical-stage biopharma developing therapies for rare diseases, gynecology, and hemophilia.

321550 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
South Korea
Address:
경기도 성남시 수정구 창업로40번길 30 6층 (시흥동, 판교아이티센터), 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TiumBio Co., Ltd. is a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutics for rare and incurable diseases. The company leverages its expertise in both small-molecule synthetic drugs and biologics to build a robust pipeline targeting areas with high unmet medical needs and significant growth potential. Its lead clinical programs include Merigolix (TU2670), an oral GnRH antagonist for treating gynecological conditions like endometriosis and uterine fibroids, and TU7710, a long-acting recombinant protein for hemophilia. Founded in 2016, TiumBio is also expanding its R&D capabilities into next-generation therapies, including bispecific antibodies and antibody-drug conjugates (ADCs), to create market value through its distinct portfolio.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for TiumBio Co., Ltd. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.8 MB

Automate Your Workflow. Get a real-time feed of all TiumBio Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for TiumBio Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
NeoImmuneTech, Inc. Logo
Develops NT-I7, a T cell-amplifying immunotherapy for cancer and infectious diseases.
United States of America 950220
Newbury Pharmaceuticals AB Logo
Develops specialty prescription drugs for Scandinavia in oncology, rare diseases & neurology.
Sweden NEWBRY
New Nordic Healthbrands AB Logo
Develops and markets herbal supplements & beauty products for natural wellness consumers globally.
Sweden NNH
Newron Pharmaceuticals S.p.A. Logo
Biopharma developing novel therapies for nervous system diseases like Parkinson's and schizophrenia.
Italy NWRN
NextCell Pharma AB Logo
Develops off-the-shelf cell therapies for autoimmune diseases like type 1 diabetes.
Sweden NXTCL
NGeneBio Co., Ltd. Logo
Provides NGS-based diagnostics, software, and liquid biopsy for precision oncology and healthcare.
South Korea 354200
NIBEC CO., LTD. Logo
Biotech CDMO creating regenerative products with peptide and biomaterial technologies.
South Korea 138610
NIPPON CHEMIPHAR CO., LTD. Logo
Develops generic drugs, allergy treatments, and novel pharmaceuticals for a global market.
Japan 4539
Nippon Shinyaku Co.,Ltd. Logo
Develops pharmaceuticals and functional foods to improve healthcare and wellbeing.
Japan 4516
NKMAX Co., Ltd. Logo
Biotech firm for NK cell therapies, global research reagents, diagnostics, and supplements.
South Korea 182400

Talk to a Data Expert

Have a question? We'll get back to you promptly.